Loading organizations...
Evotec is a global life sciences company focused on comprehensive drug discovery and development services that is currently headquartered in Hamburg, Germany. The organization integrates artificial intelligence, advanced technologies, and proprietary disease modeling platforms like PanOmics to accelerate the progression of novel therapies from their initial concept to commercialization. Operating across small molecules, biologics, and cell therapies, the firm employs more than 4,800 personnel across its research and manufacturing facilities in Europe and the United States. Its flexible partnership model serves a broad client base that includes all of the top twenty global pharmaceutical corporations, various academic institutions, and over 800 biotechnology companies. The company also operates a dedicated contract development and manufacturing organization for biologics through its wholly owned subsidiary, known as Just-Evotec Biologics. The enterprise was originally founded in 1993 as Evotec BioSystems GmbH.
Key people at Evotec.
Evotec was founded in 1993 by Rudolf Rigler (Co-Founder) and Ulrich Aldag (Co-Founder & Managing Director) and Charles Weissmann (Co-Founder) and Heinrich M. Schulte (Co-Founder) and Freimut Leidenberger (Co-Founder) and Manfred Eigen (Co-Founder) and Karsten Henco (Co-Founder).
Key people at Evotec.
Evotec has 9 tracked investments across 6 companies. The latest tracked deal is $96.0M Series A in Cajal Neuroscience in November 2022.
Evotec was founded in 1993 by Rudolf Rigler (Co-Founder) and Ulrich Aldag (Co-Founder & Managing Director) and Charles Weissmann (Co-Founder) and Heinrich M. Schulte (Co-Founder) and Freimut Leidenberger (Co-Founder) and Manfred Eigen (Co-Founder) and Karsten Henco (Co-Founder).
